Chronic Kidney Disease Segment Drives Global Ketoanalogue Market Demand
The global ketoanalogue for kidney disease market is witnessing steady growth, driven by the rising prevalence of chronic kidney disease (CKD), increasing awareness of nutritional management, and growing demand for treatments that help delay disease progression. The market was valued at US$ 214.7 million in 2021 and is projected to expand at a CAGR of 6.5% from 2022 to 2031, reaching more than...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek